Companies › IO Biotech
3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IO102-IO103 Dual peptide antigen cancer vaccine (IDO peptide antigen IO102 and PD-L1 peptide antigen I | IDO1, CD274 | Phase 3 | Metastatic Melanoma | Sep 2027 |
| IO102 IDO1 peptide | IDO1 | Phase 2 | Melanoma | Jan 2027 |
| IO103 PD-L1 peptide | CD274 | Phase 2 | Melanoma | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05280314 | IO102 | Phase 2 | Melanoma | Oncology | Jan 2027 |
| NCT05280314 | IO103 | Phase 2 | Melanoma | Oncology | Jan 2027 |
| NCT05155254 | IO102-IO103 | Phase 3 | Metastatic Melanoma | Oncology | Sep 2027 |
AstraZeneca Pfizer ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan) Shanghai Henlius Biotech
Seattle Project CellCentric Criterium Tesaro iOnctura
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.